Citigroup maintains Becton Dickinson at Buy, raises price target to $241 from $208
Citigroup kept its Buy rating on Becton Dickinson (BDX) and increased its price target to $241 from $208, suggesting a 13.7% upside from its Nov 6 close of $211.88. Recent analyst price targets for BDX range from $165 to $242.
How this was made

The 30-second read
Why it matters
The upgrade could trigger buying pressure, but magnitude depends on broader market sentiment.
Market read
Analyst target raise provides a modest trading signal for BDX.
What to watch
Potential supply‑chain constraints could offset upside.
Background
Analyst price target adjustments are common catalysts for short‑term moves.
Ticker impact
Citigroup raised its price target on Becton Dickinson to $241 from $208.
potential upward pressure as investors price in higher target
Target increase reflects improved outlook, likely to attract buying interest.
Market effects
May lift sentiment in medical devices sector.
US healthcare stocks could see modest gains.
Limited to investors tracking US med‑tech equities.
Counterpoint
Target raise may be premature if upcoming earnings miss expectations.
Key entities
- AnalystCitigroup
Equity research firm raising BDX target.
- CompanyBecton Dickinson
Medical device manufacturer.



